Chapter 13. Cationic Lipid Complexes to Target Tumor Endothelium

  1. Dietmar W. Siemann3,4
  1. Uwe Michaelis1 and
  2. Michael Teifel2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch13

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Michaelis, U. and Teifel, M. (2006) Cationic Lipid Complexes to Target Tumor Endothelium, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch13

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    MediGene AG, Lochhammer Strasse 11, D-82152 Planegg/Martinsried, Germany

  2. 2

    Zentaris GmbH, Drug Discovery – Pharmacology and Toxicology, Weismüllerstrasse 45, D-60314 Frankfurt/Main, Germany

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436



  • Vascular disrupting agents (VDAs);
  • low-molecular-weight cytotoxic drugs;
  • tumor vascular targeting and cationic liposomes;
  • cationic lipid complexes targeting tumor endothelium;
  • cationic liposomes as drug carriers;
  • cationic lipid and gene transfer;
  • chemotherapeutic drugs and proteins;
  • intravenously administered cationic lipid complexes;
  • cationic-liposome-based-vascular-targeting agents


This chapter contains sections titled:

  • Introduction

  • Tumor vascular targeting by cationic liposomes

  • Potential targets for cationic lipid complexes on tumor endothelial cells

  • Cationic liposomes as drug carriers

  • Side-effects of intravenously administered cationic lipid complexes

  • Preclinical data

  • Clinical data

  • Conclusion

  • Acknowledgments

  • References